Singlomics utilizes single-cell sequencing technology to develop antibody drugs targeting tumors and autoimmune diseases. Their high-throughput screening platform enhances the accuracy of drug development, significantly reducing the time and failure rates associated with bringing new therapies to market.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody drug development for tumors and autoimmune diseases is a lengthy and expensive process with high failure rates due to the complexity of identifying and validating effective therapeutic targets. Conventional screening methods often lack the precision needed to isolate antibodies with the desired specificity and functional activity.
Solution
Singlomics leverages single-cell sequencing to enhance antibody drug discovery, addressing the limitations of traditional methods. Their platform enables high-throughput screening of B cells to identify rare antibody candidates with specific binding profiles and functional properties. By analyzing the transcriptome and immunoglobulin genes of individual cells, Singlomics can pinpoint antibodies that target specific disease-relevant epitopes. This approach increases the accuracy and efficiency of drug development, accelerating the identification of promising therapeutic candidates and reducing the risk of late-stage failures.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies focused on developing novel antibody therapeutics for oncology and autoimmune disorders.
Features
- High-throughput single-cell sequencing of B cells to identify diverse antibody candidates.
- Analysis of paired heavy and light chain sequences to ensure antibody integrity and functionality.
- Proprietary bioinformatics pipeline for identifying antibodies with desired binding specificities and functional activities.
- Functional assays to validate antibody efficacy in vitro and in vivo.
- Target identification and validation using single-cell RNA sequencing data.
- Antibody humanization and optimization to improve safety and efficacy.